Literature DB >> 27025507

Causes of death in 2877 patients with myelodysplastic syndromes.

Kathrin Nachtkamp1, Romina Stark2, Corinna Strupp2, Andrea Kündgen2, Aristoteles Giagounidis3, Carlo Aul3, Barbara Hildebrandt4, Rainer Haas2, Norbert Gattermann2, Ulrich Germing2.   

Abstract

Patients with myelodysplastic syndromes face a poor prognosis. The exact causes of death have not been described properly in the past. We performed a retrospective analysis of causes of death using data of 3792 patients in the Düsseldorf registry who have been followed up for a median time of 21 months. Medical files as well as death certificates were screened and primary care physicians were contacted. Death after AML evolution, infection, and bleeding was considered to be clearly disease-related. Further categories of causes of death were heart failure, other possibly disease-related reasons, such as hemochromatosis, disease-independent reasons as well as cases with unclear causes of death. Median age at the time of diagnosis was 71 years. At the time of analysis, 2877 patients (75.9 %) had deceased. In 1212 cases (42.1 %), the exact cause of death could not be ascertained. From 1665 patients with a clearly documented cause of death, 1388 patients (83.4 %) succumbed directly disease-related (AML (46.6 %), infection (27.0 %), bleeding (9.8 %)), whereas 277 patients (16.6 %) died for reasons not directly related with myelodysplastic syndromes (MDS), including 132 patients with cardiac failure, 77 non-disease-related reasons, 23 patients with solid tumors, and 45 patients with possibly disease-related causes like hemochromatosis. Correlation with IPSS, IPSS-R, and WPSS categories showed a proportional increase of disease-related causes of death with increasing IPSS/IPSS-R/WPSS risk category. Likewise, therapy-related MDS were associated with a higher percentage of disease-related causes of death than primary MDS. This reflects the increasing influence of the underlying disease on the cause of death with increasing aggressiveness of the disease.

Entities:  

Keywords:  Causes of death; Myelodysplastic syndromes; Prognosis

Mesh:

Year:  2016        PMID: 27025507     DOI: 10.1007/s00277-016-2649-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  25 in total

1.  Monocyte function in patients with myelodysplastic syndrome.

Authors:  Daniel A Pollyea; Brenna R Hedin; Brian P O'Connor; Scott Alper
Journal:  J Leukoc Biol       Date:  2018-04-14       Impact factor: 4.962

2.  Risk and timing of cardiovascular death among patients with myelodysplastic syndromes.

Authors:  Andrew M Brunner; Traci M Blonquist; Gabriela S Hobbs; Philip C Amrein; Donna S Neuberg; David P Steensma; Gregory A Abel; Amir T Fathi
Journal:  Blood Adv       Date:  2017-10-18

3.  Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes.

Authors:  Raphael Itzykson; Simon Crouch; Erica Travaglino; Alex Smith; Argiris Symeonidis; Eva Hellström-Lindberg; Guillermo Sanz; Jaroslav Čermák; Reinhard Stauder; Chiara Elena; Ulrich Germing; Moshe Mittelman; Saskia Langemeijer; Krzysztof Mądry; Aurelia Tatic; Mette Skov Holm; Antonio Medina Almeida; Aleksandar Savic; Njetočka Gredelj Šimec; Elisa Luño; Dominic Culligan; Agnes Guerci-Bresler; Luca Malcovati; Corine van Marrewijk; David Bowen; Theo de Witte; Pierre Fenaux
Journal:  Blood Adv       Date:  2018-08-28

4.  Therapy for lower-risk MDS.

Authors:  Hetty E Carraway; Caner Saygin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 5.  Treatment of low-risk myelodysplastic syndromes.

Authors:  Valeria Santini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

6.  Effect of thrombopoietin receptor agonist on health-related quality of life and platelet transfusion burden for patients with myelodysplastic syndromes: a systematic review and meta-analysis.

Authors:  Kai Wang; Yacong Shao; Changgui Li; Jizhang Bao; Wenwei Zhu; Yongming Zhou
Journal:  Ann Hematol       Date:  2022-08-17       Impact factor: 4.030

Review 7.  Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.

Authors:  Katherine Linder; Premal Lulla
Journal:  Hum Vaccin Immunother       Date:  2021-05-03       Impact factor: 3.452

8.  NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.

Authors:  Elizabeth A Griffiths; Pragya Srivastava; Junko Matsuzaki; Zachary Brumberger; Eunice S Wang; Justin Kocent; Austin Miller; Gregory W Roloff; Hong Yuen Wong; Benjamin E Paluch; Linda G Lutgen-Dunckley; Brandon L Martens; Kunle Odunsi; Adam R Karpf; Christopher S Hourigan; Michael J Nemeth
Journal:  Clin Cancer Res       Date:  2017-09-25       Impact factor: 13.801

Review 9.  Management of the Older Patient with Myelodysplastic Syndrome.

Authors:  Rory M Shallis; Amer M Zeidan
Journal:  Drugs Aging       Date:  2021-08-03       Impact factor: 3.923

Review 10.  Infections in Myelodysplastic Syndrome in Relation to Stage and Therapy.

Authors:  Giuseppe Leone; Livio Pagano
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-07-01       Impact factor: 3.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.